TGFB1 and colorectal carcinoma: Mechanistically, we showed that blocking p65BTK in drug-resistant cells abolished a 5-FU-elicited TGFB1 protective response and triggered E2F-dependent apoptosis, thus giving a proof-of-concept for the use of BTK inhibitors in combination with 5-FU as a novel therapeutic approach in CRC patients [85].